title: Hemostatic therapy for intracerebral hemorrhage.
abstract: Despite the highest mortality and morbidity of all forms of stroke, few advances have been made in the management of intracerebral hemorrhage (ICH). Besides specialized care in the stroke or neurologic intensive care unit, until very recently no specific therapies have been shown to improve outcome after ICH. Ventilatory support, blood pressure reduction, intracranial pressure monitoring, osmotherapy, fever control, seizure prophylaxis, and nutritional supplementation are the cornerstones of supportive care in the intensive care unit. Recently, a phase II trial of recombinant activated factor VII (NovoSeven; Novo Nordisk, Bagsvaerd, Denmark) reduced hematoma expansion, mortality, and disability when given within 3 hours of ICH onset. A phase III trial to confirm these results is now in progress.
authors.forename: Fred
authors.initials: F
authors.lastname: Rincon
authors.forename: Manuel M
authors.initials: MM
authors.lastname: Buitrago
authors.forename: Stephan A
authors.initials: SA
authors.lastname: Mayer
mesh_terms: D002543:Cerebral Hemorrhage / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D003029:Coagulants / Q000627:therapeutic use*; D006487:Hemostasis; D006801:Humans; D011379:Prognosis; D011859:Radiography; D020246:Venous Thrombosis / Q000517:prevention & control
chemical_list: D003029:Coagulants